Ophthalmic Consultants of Long Island Inject Patient With JETREA

Daniel Kiernan, MD, of Ophthalmic Consultants of Long Island injected a patient suffering from vitreo-macular adhesion with JETREA, a dilution of ocriplasmin that is the first FDA approved drug to treat VMA, according to a report by the Times Union.

Advertisement

This procedure was the first injection of the drug on Long Island.

JETREA, approved by the FDA in 2012, will be available at other Ophthalmic Consultants of Long Island locations.

More Articles on Ophthalmology:
Dr. Ryan Walsh Joins Medical College of Wisconsin
Miller School of Medicine, International Team Discover Seven Genes Linked to Macular Degeneration
Report Estimates Optical Imaging Market Worth $1.9B by 2018

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Ophthalmology

Advertisement

Comments are closed.